A report today from an international association of life sciences companies suggests that the private sector is making progress in meeting its commitment to help solve the antimicrobial resistance (AMR) crisis, but much work remains.
The progress report from the AMR Industry Alliance, a collection of more than 100 companies and trade associations representing the pharmaceutical, biotechnology, generics, and diagnostics industries, indicates that industry investment in AMR-related research and development is significant and has resulted in a handful of new products in development, including antibiotics, vaccine candidates, and diagnostic products.